Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based Survey

| June 1, 2013 | 0 Comments

by Michelle Stewart, PhD; Adam Butler; Larry Alphs, MD, PhD; Phillip B. Chappell, MD; Douglas E. Feltner, MD; William R. Lenderking, PhD; Atul R. Mahableshwarkar, MD; Clare W. Makumi, PharmD, MBA; Sarah Dubrava, MS; and the ISCTM Suicidal Ideation and Behavior Assessment Working Group

Dr. Stewart is Sr. Director, Outcomes Research, Specialty Care Medicines Development Group, Pfizer, Inc., Groton, Connecticut; Dr. Butler is with Bracket, Wayne, Pennsylvania; Dr. Alphs is Therapeutic Area Leader Psychiatry, Janssen Scientific Affairs, Princeton, New Jersey; Dr. Chappell is with Pfizer Inc., Groton, Connecticut, and Yale School of Medicine, Child Study Center, New Haven, Connecticut; Dr. Feltner is Douglas E. Feltner LLC, Novi, Michigan; Dr. Lenderking is with United Biosource Inc., Lexington, Massachusetts; Dr. Mahableshwarkar is with Takeda Global Research and Development Center, Inc., Deerfield, Illinois; Dr. Makumi is with GlaxoSmithKline, Research Park Triangle, North Carolina; and Ms. DuBrava is with Pfizer Inc., Groton, Connecticut.

Innov Clin Neurosci. 2013;10(5ā€“6 Suppl A):20Sā€“28S

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags:

Category: Drug Development, Mood Disorders, Neurology, Original Research, Past Articles, Psychiatry, Suicidality, Supplements, Trial Methodology

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.